1. Introduction {#sec1-jcm-08-01179}
===============

The prevalence of myopia has been increasing in recent years and is doing so at a remarkable rate in East Asian countries, including Japan, where the prevalence rate of myopia with a refraction of −0.5 diopters (D) or less has reached approximately 40% \[[@B1-jcm-08-01179],[@B2-jcm-08-01179]\]. A systematic review with meta-analysis suggested that the prevalence of myopia and high myopia would drastically increase in the next 30 years, with an estimation that the prevalence of myopia and high myopia would reach 5 billion and 1 billion, respectively, and that 40% of blindness would be due to myopia \[[@B3-jcm-08-01179]\]. Along with the increase in myopia, it is expected that the prevalence of high myopia and its associated diseases, such as myopic maculopathy, retinal detachment, and glaucoma, will increase \[[@B3-jcm-08-01179]\]. The medical cost accompanied by the increase in myopia-associated diseases is also anticipated to expand, and therefore, ways to suppress myopia are becoming important \[[@B4-jcm-08-01179]\]. Studies concerning myopia prevention are being more vigorously pursued than ever, even though the etiology of myopia is now better understood than before. Newly developed interventions to suppress myopia progression have been demonstrated to be effective by studies performed in the past 20 years and should be implemented from now on \[[@B5-jcm-08-01179],[@B6-jcm-08-01179]\]. Outdoor activities, atropine eye drops, and orthokeratology lenses for the suppression of myopia are under investigation, and various additional approaches are being considered \[[@B7-jcm-08-01179]\]. Several studies aimed at developing remedies to halt myopia progression have been performed and recently showed significant progress, with definitive results. Furthermore, we should take more actions to explore the advancement of countermeasures, including food factors and supplements.

As a factor related to myopia, the light environment has been considered to be significant \[[@B8-jcm-08-01179],[@B9-jcm-08-01179],[@B10-jcm-08-01179]\]. Violet light, which has a wavelength in the range of 360 to 400 nm in the visible light region, had a suppressive effect on myopia \[[@B11-jcm-08-01179],[@B12-jcm-08-01179],[@B13-jcm-08-01179]\]. Among various myopia-related genes, early growth response 1 (*Egr1*) was shown to be upregulated by violet light exposure both in vivo and in vitro \[[@B11-jcm-08-01179]\]. Egr1 is a transcriptional factor known as a myopia suppressive agent functioning in the feedback mechanism for axial ocular growth \[[@B11-jcm-08-01179],[@B14-jcm-08-01179],[@B15-jcm-08-01179]\]. Two hundred and seven natural compounds and chemical reagents were screened based on the activity of Egr1 in vitro, crocetin showed the highest activation of Egr1, and this activation was also shown to be dose-dependent \[[@B16-jcm-08-01179]\]. Crocetin is an active natural compound of saffron and *Gardenia jasminoides* and is used as a traditional herbal medicine \[[@B17-jcm-08-01179]\]. Crocetin is a unique carotenoid, and contains a short carbon chain length and carboxyl groups at both ends of the carbon chain \[[@B17-jcm-08-01179]\]. Crocetin has a strong antioxidant effect, inhibiting cellular oxidative damage mediated by reactive oxygen species derived from xanthine oxidase \[[@B16-jcm-08-01179],[@B18-jcm-08-01179]\]. In animal and human studies, crocetin has been shown to have a variety of pharmacological effects \[[@B16-jcm-08-01179],[@B19-jcm-08-01179],[@B20-jcm-08-01179],[@B21-jcm-08-01179]\]. Crocetin has also been demonstrated to have the potential to treat ocular diseases, such as age-related macular degeneration, glaucoma, and diabetic maculopathy, as well as neurological or circulatory diseases, including Alzheimer's disease and cardiac ischemia \[[@B22-jcm-08-01179],[@B23-jcm-08-01179]\].

In this study, we performed a placebo-controlled randomized clinical trial of crocetin treatment for children.

2. Materials and Methods---Randomized Clinical Trial {#sec2-jcm-08-01179}
====================================================

2.1. Study Design {#sec2dot1-jcm-08-01179}
-----------------

This was a multicenter prospective randomized double-blind placebo-controlled trial. The study was performed in compliance with the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving Human Subjects, and local regulatory requirements, as well as under the approval of all study institutional review boards (IRB) and ethics committees. This trial was approved by the IRB of Keio University School of Medicine (approval no. 20180079) and Medical Corporation Heishinkai OPHAC Hospital Ethical Review Committee (approval no. 1011PC). This trial was also registered by Japic Clinical Trials Information with the registration number JapicCTI-173777. This randomized control trial followed CONSORT guidelines.

2.2. Study Organization {#sec2dot2-jcm-08-01179}
-----------------------

Participants were recruited by the Medical Corporation Heishinkai ToCROM Clinic in Tokyo and OPHAC Hospital in Osaka, Japan.

2.3. Participants {#sec2dot3-jcm-08-01179}
-----------------

Participants were enrolled from November 2017 to February 2018, were on trial from November 2017 to July 2018, and were followed-up for 24 weeks. As for the sample size, this study was launched as a pilot study because similar studies had not previously been conducted. Therefore, no sample size calculation was performed. We planned to recruit 80 participants, that is, 40 in each group, which we considered a reasonable number as a pilot study. By the end of the initially defined recruiting period on 20th January 2017, we could recruit only 49 participants. Hence, we extended the recruiting period for one month until 14th February, at which point the number of participants reached 69, which was approximately 86% of the initial recruitment. At that point, we closed the enrollment.

Children who met all the following selection criteria were included in the study: (1) Between 6 and 12 years of age at the initial diagnosis; (2) myopia with a spherical equivalent refraction (SER) from −1.50 D to −4.50 D at the initial diagnosis; (3) astigmatism of 1.50 D or less; (4) having no eye disease histories except refractive error; (5) using eyeglasses for myopia correction; (6) of whom at least one parent had myopia; (7) being able to comply with the instructions from the principal investigator or sub-investigator (hereinafter referred to as "investigator"), including the administration method of the assigned investigational product and periodic examination schedule; (8) being able to use eyeglasses for myopia correction prescribed by the investigator during the evaluation period. Informed consent was obtained from study subjects (hereinafter referred to as "subject(s)") and the supplemental consent was obtained from a legal guardian such as their parents; or the surrogate's written consent to participate in the study was obtained from a legal guardian such as their parents and the written informed assent to participate in the study was obtained from subjects themselves because the selection criteria of this trial included children aged between 6 and 12 years old.

Children who met at least one of the following exclusion criteria were excluded from the study: (1) Anisometropia exceeding 1.50 D; (2) corrected visual acuity of one eye was less than 1.0; (3) wearing contact lenses; (4) having a history of allergy to ingredients to be taken in the study (crocetin, safflower oil, gelatin, glycerin fatty acid ester, glycerin, caramel, and titanium dioxide), or cycloplegics/eye-drop anesthetics to be used at diagnosis (tropicamide phenylephrine hydrochloride ophthalmic solution, cyclopentolate hydrochloride ophthalmic solution, and oxybuprocaine hydrochloride ophthalmic solution), and fluorescein, etc.; (5) having a history of participation in any other clinical study or research similar to this study; (6) currently using drugs and supplements which might affect the evaluation; (7) having a history of other methods to suppress myopia progression, including wearing orthokeratology lenses, wearing bifocal or progressive power glasses, and the use of atropine ophthalmic solution; (8) having a history of other eye complications or systemic complications.

2.4. Randomization and Masking {#sec2dot4-jcm-08-01179}
------------------------------

The participants were randomly assigned to two groups: the control group and the crocetin group. The participants of the control group took placebo capsules and those of the crocetin group took crocetin capsules. The double-blinded method was implemented by way of a block randomization method, where blocks were determined by sex, age, and refraction. Refraction (D) was divided into two groups: "−1.5 or more but less than −3.0" and "−3.0 or more but less than −4.5". Each block had four cases. Masking was performed in the following way: experimental materials and their packages were prepared to be undetectable from the outside, an independent third person assigned the experimental drugs, and he or she sealed them.

2.5. Intervention {#sec2dot5-jcm-08-01179}
-----------------

A crocetin soft capsule encompassed 7.5 mg of crocetin and safflower oil as the main substrate. A placebo soft capsule contained safflower oil instead of crocetin. A soft capsule was taken orally once a day with a sufficient amount of water for 24 weeks in a row.

2.6. Procedure for Follow-Up Examinations {#sec2dot6-jcm-08-01179}
-----------------------------------------

At the participants' initial visit, details about the study design and methodology and their rights as participants were provided. After obtaining written informed consent from them and their parents, we conducted visual acuity examinations, subjective refraction measurements, objective refraction measurements, and axial length (AL) measurements. During the subjective refraction measurements, we measured the best-corrected visual acuity (BCVA). Subjective refraction (full correction of myopia under cycloplegia) was used to prescribe the lens power of the spectacles to be worn during the trial. In the objective refraction test, we measured objective refraction using closed-field-type auto ref-keratometers (ARK-730A series, NIDEK, Tokyo, Japan) with a step of 0.01 D. Cycloplegic objective refraction measurements were performed 1 h after the application of 1% cyclopentolate hydrochloride eyedrops (Cyplegin^®^ 1% ophthalmic solution, Santen, Osaka, Japan). We used the IOLMaster 700 (Carl Zeiss Meditec, Jena, Germany) to measure the AL. Optical Coherence Tomography (OCT) (Cirrus HD-OCT plus (model 500), Carl Zeiss, Jena, Germany) was performed for all participants at each visit.

Interviews were conducted to elicit information such as age, gender, number of myopic parents, their living environment, and their lifestyle, including time of sunlight exposure, time of near-work, sleep duration, and physical activity (calculated from the International Physical Activity Questionnaire (IPAQ)) \[[@B24-jcm-08-01179]\]. Times of near-work and sunlight exposure were calculated by weighted means of 5 weekdays and 2 days of the weekend. We conducted follow-up examinations at 4, 12, and 24 weeks after the first visit. In the follow-up examinations, we measured visual acuity with the current spectacles, BCVA, subjective refraction, noncycloplegic objective refraction, cycloplegic objective refraction, and AL. AL was measured at 4 weeks, 12 weeks, and 24 weeks after the administration of crocetin. Cycloplegic objective refraction was measured at 4 and 24 weeks after administration. The measurements of BCVA, subjective refraction, objective refraction, and AL were performed as described above. If the visual acuity with the current spectacles dropped to \<1.0 (20/20), the lens power of the spectacles was replaced on the basis of the subjective refraction under cycloplegia. As for adverse events, we conducted a survey of all adverse events which occurred from the initial check-up to the end of this research and described them in the case report documents.

2.7. Outcomes {#sec2dot7-jcm-08-01179}
-------------

The primary and secondary outcomes were the change of AL and the cycloplegic objective refraction for 24 weeks.

2.8. Choroidal Thickness Measurement {#sec2dot8-jcm-08-01179}
------------------------------------

An OCT (Cirrus HD-OCT plus (model 500), Carl Zeiss, Jena, Germany) was used to analyze data. The outer margin of the retinal pigment epithelium (RPE) was considered as the anterior margin of the choroid and the choroidal--scleral interface as the posterior margin of the choroid. The image was exported to ImageJ (National Institutes of Health, Bethesda, MD, USA) and the borders of the choroid were drawn by connecting the marked locations, leading to a calculation of the measured choroidal thickness at the center of the fovea. A change in the choroidal thickness was evaluated from the first visit to the last visit. Assessment of the choroidal thickness was conducted manually and the same person (who was completely masked) carried out all the analysis in the baseline and final visits.

2.9. Statistical Analysis {#sec2dot9-jcm-08-01179}
-------------------------

Myopia progression (changes in cycloplegic objective SER and AL after 24 weeks) can be affected by factors such as age, gender, and some environmental factors, including sleep duration and times of near-work and outdoor activity. Although randomized assignment would help in correcting the effect of such factors on the outcomes, residual imbalances between the crocetin group and the placebo group could affect the results. To minimize the effect of these factors, we built a linear mixed-effects model and compared changes in myopia progression between the two groups.

Upon comparison of the two groups, a restricted maximum-likelihood (REML) estimation method was used to compare variations from the baseline. A mixed-effects model for repeated measures (MMRM) was used with a Variance--Covariance Structure of repeated data postulating Spatial Power. The statistical significance was defined as *p* \< 0.05. The null hypothesis was that there would be no difference in myopia progression after 24 weeks between the two groups. In this model, we used all the measurements obtained from both eyes. The participant identification number was included as a random effect in this model. The fixed effects in this model were the treatment group (the placebo group and the crocetin group), baseline age, gender, baseline time of near-work, baseline time of outdoors (sunlight exposure), baseline sleeping duration, setting right/left eye, visit (week 4, week 12, week 24) and interaction of group and visit. Times of near-work and outdoor activity were calculated by weighted means of 5 weekdays and 2 days of the weekend.

We calculated the parameter estimates, standard error, and *p*-values from a *t*-test of effects in the model. Least Squares Means of changes in AL from the baseline between the groups per visit were calculated from the interaction term and compared using a *t*-test. We also analyzed changes in cycloplegic objective SER at each visit (week 4, week 24) from the baseline with MMRM. We used a compound-symmetry covariance matrix in this analysis because there were two visit points. All statistical analyses were performed using SAS 9.4 Foundation for Microsoft Windows for x64 (SAS Institute Inc., Cary, NC, USA).

A *t*-test was used for the comparison of age, height, and body weight and a Mann--Whitney U test was applied for the non-parametric data at the baseline. Fisher's exact test was used for categorical variables. A *t*-test was also used for the comparison of the change in choroidal thickness.

3. Results---Randomized Clinical Trial {#sec3-jcm-08-01179}
======================================

3.1. Flow of Participants {#sec3dot1-jcm-08-01179}
-------------------------

A total of 69 children were enrolled in this trial. Of these, 30 participants were assigned to the placebo group and 39 participants to the crocetin group ([Figure 1](#jcm-08-01179-f001){ref-type="fig"}). During the follow-up period, two participants dropped out. One of them was due to noncompliance with 75% of the assignment, and the other failed to receive the check-up because they were too busy. As a result, a total of 67 children completed this trial. A total of 67 participants (30 in the placebo group, 37 in the crocetin group) completed the final examination. The investigators, including orthoptists and ophthalmologists, were masked with regard to the allocation of the treatment group.

3.2. Participant Profiles {#sec3dot2-jcm-08-01179}
-------------------------

The participants' profiles are shown in [Table 1](#jcm-08-01179-t001){ref-type="table"}. No significant differences were found between the two groups with respect to age or gender. In addition, the SER and the AL at the first visit showed no significant differences. The mean ages of the participants in the placebo and the crocetin groups were 10.1 ± 1.3 years (mean ± SD) and 10.4 ± 1.2 years; the mean SERs were −3.45 ± 1.00 and −3.45 ± 0.25 D; and the mean of ALs were 25.10 ± 0.77 and 24.91 ± 0.89 mm, respectively. No significant differences were found between the two groups, except in terms of the sunlight exposure time.

3.3. Adverse Events {#sec3dot3-jcm-08-01179}
-------------------

No adverse effects associated with crocetin administration were reported during the clinical study. All adverse events reported during the study were not associated with crocetin administration ([Table S1](#app1-jcm-08-01179){ref-type="app"}).

3.4. Comparison of Myopia Progression after 24 Weeks {#sec3dot4-jcm-08-01179}
----------------------------------------------------

The participants' backgrounds were adjusted using a linear mixed-effects model to verify the myopia control effect of crocetin. [Table 2](#jcm-08-01179-t002){ref-type="table"}, [Table 3](#jcm-08-01179-t003){ref-type="table"} and [Table 4](#jcm-08-01179-t004){ref-type="table"} demonstrate changes in various myopia-relevant parameters over the duration of our study.

[Table 2](#jcm-08-01179-t002){ref-type="table"} shows the results of fitting the model to the cycloplegic SER change after 24 weeks. The difference between the mean adjusted changes in SER after 24 weeks in the crocetin group and those in the placebo group was 0.08 ± 0.04 D/24 weeks (mean ± standard error). [Table 3](#jcm-08-01179-t003){ref-type="table"}a and [Figure 2](#jcm-08-01179-f002){ref-type="fig"}a show adjusted mean changes in the SER at week 4 and week 24 visits. The change in adjusted mean SER in the crocetin group was significantly smaller than that in the placebo group (*p* = 0.028 and *p* = 0.049, respectively) ([Table 3](#jcm-08-01179-t003){ref-type="table"}a, [Figure 2](#jcm-08-01179-f002){ref-type="fig"}a).

[Table 4](#jcm-08-01179-t004){ref-type="table"} shows the results of fitting the model to the AL elongation after 24 weeks. The difference between the mean adjusted AL elongation after 24 weeks in the crocetin group and that in the placebo group was −0.03 ± 0.01 mm/24 weeks. The change in AL in the crocetin group was significantly smaller than that in the placebo group (*p* = 0.046). [Table 3](#jcm-08-01179-t003){ref-type="table"}b and [Figure 2](#jcm-08-01179-f002){ref-type="fig"}b show the mean adjusted AL elongation at week 4, 12, and 24 visits. The changes in the adjusted mean AL in the crocetin group were significantly smaller than those in the placebo group (*p* = 0.020 for the 12-week visit and *p* = 0.046 for the 24-week visit) ([Table 3](#jcm-08-01179-t003){ref-type="table"}b, [Figure 2](#jcm-08-01179-f002){ref-type="fig"}b).

The results were obtained by linear mixed-effects model analysis. (a) The adjusted means of SER changes in the crocetin group were significantly (*p* = 0.0275 and *p* = 0.0487) smaller than those in the placebo group at 4 and 24 weeks, respectively. (b) The adjusted means of axial length elongation in the crocetin group were significantly (*p* = 0.020 and *p* = 0.046) smaller than those in the placebo group at 12 and 24 weeks, respectively. Black lines show the crocetin group and gray lines show the placebo group. Error bars show standard errors. \* *p* \< 0.05.

3.5. Change in Choroidal Thickness over 6 Months {#sec3dot5-jcm-08-01179}
------------------------------------------------

Changes in the choroidal thickness were evaluated during the administration period. The choroidal thickness change was −9.2 ± 75.5 μm in the placebo group and 34.1 ± 49.1 μm in the crocetin group, and the difference between the groups was statistically significant (*p* \< 0.001, [Figure 3](#jcm-08-01179-f003){ref-type="fig"}). These data indicated that the choroidal thickness was significantly increased by crocetin administration.

The choroidal thickness in the crocetin group was significantly (*p* \< 0.001) thicker than that in the placebo group. \*\*\* *p* \< 0.001. Bars represent mean ± standard deviations.

4. Discussion {#sec4-jcm-08-01179}
=============

Crocetin, one of the carotenoids which have antioxidant activity, has been shown to have the potential to suppress the progression of myopia in mice \[[@B16-jcm-08-01179]\]. Therefore, we established a two-center prospective double-blind randomized controlled trial with subjects of 69 children aged from 6 to 12 to verify the myopia-suppressive effect of crocetin. Verification by mixed-effects models showed that the change in refraction and axial elongation were both suppressed. This trial demonstrated that crocetin had a significant suppressive effect against myopia progression and AL elongation in children.

Near-work and outdoor activity, including sunlight exposure, are the main environmental factors affecting myopia progression \[[@B25-jcm-08-01179],[@B26-jcm-08-01179],[@B27-jcm-08-01179]\]; we investigated the time of near-work and sunlight exposure using the questionnaire in the current study. Coincidentally, there was a significant difference in the time of sunlight exposure at the baseline between the two groups. Therefore, we used a mixed-effects model in this clinical trial with repeated measurements \[[@B28-jcm-08-01179]\]. Furthermore, we adopted sleeping time as one of the covariates because it was reported to have a relationship with myopia \[[@B29-jcm-08-01179],[@B30-jcm-08-01179]\]. Although the time of sunlight exposure was significantly different between the two groups at the baseline, the results of the mixed-effects model showed that treatments and time of sunlight exposure were the significant factors affecting SER change for 24 weeks. The results also showed that treatments, age, and sex were the significant factors affecting AL change for 24 weeks in accordance with past papers \[[@B16-jcm-08-01179],[@B27-jcm-08-01179],[@B31-jcm-08-01179]\], indicating the effectiveness of the crocetin against myopia progression in children.

Atropine has been reported to have the highest suppressive effect on myopia progression \[[@B7-jcm-08-01179]\], and the calculated suppression rates of SER and AL by administering 0.01% atropine eye drops for 24 weeks were 27.2% and 12.2% \[[@B32-jcm-08-01179]\], respectively. In contrast, the suppression rates of SER and AL in the current crocetin group were 19.5% and 16.7%, respectively. The current crocetin study did not surpass the atropine studies \[[@B7-jcm-08-01179]\] regarding suppression of the change in SER, but it showed a more potent effect on AL elongation. Since atropine eye drops have been used in clinical settings to prevent myopia progression, the changes in the SER and AL treated by not only atropine, but also crocetin, may be considered as clinically meaningful.

Choroidal thickness was reported to become thinner in myopic patients, and associations between choroidal thickness under the central fovea and refraction or axial elongation were also reported \[[@B33-jcm-08-01179],[@B34-jcm-08-01179],[@B35-jcm-08-01179],[@B36-jcm-08-01179]\]. Crocetin has been demonstrated to have various positive effects in human and animal models \[[@B16-jcm-08-01179],[@B18-jcm-08-01179],[@B19-jcm-08-01179],[@B20-jcm-08-01179],[@B21-jcm-08-01179]\]. As the choroid is a structure with a high vascularity, it could be an effect of crocetin to increase blood flow in the choroid, which may result in an increase of the choroidal thickness ([Figure 3](#jcm-08-01179-f003){ref-type="fig"}). In fact, crocetin has been reported to improve pulmonary, cerebral, and ocular blood flow \[[@B37-jcm-08-01179],[@B38-jcm-08-01179],[@B39-jcm-08-01179]\]. The mechanisms of the blood flow increase caused by crocetin may possibly be the inhibition of protein kinase C activity in vascular smooth muscle cells \[[@B40-jcm-08-01179]\] and induction of nitric oxide production in vascular endothelial cells, as previously reported \[[@B41-jcm-08-01179]\]. These functions of crocetin that affect vascular dynamics may result in increased choroidal thickness, eventually leading to a suppressive effect against myopia in children. Crocetin has been particularly consumed in countries where the prevalence of myopia is relatively low \[[@B42-jcm-08-01179],[@B43-jcm-08-01179],[@B44-jcm-08-01179],[@B45-jcm-08-01179]\]. Although the mechanism of the myopia-suppressive effect of crocetin has not been well-characterized, the change in the choroidal thickness in the crocetin group was significantly thicker than that in the placebo group. Similar results were also observed in the mouse model \[[@B16-jcm-08-01179]\]. Thickening of the choroid is one of the possible mechanisms of the myopia-suppressive effect of crocetin.

Regarding the safety of dietary crocetin, a previous study showed that no adverse effect was seen in adults after the oral administration of a crocetin dose of 7.5--22.5 mg \[[@B17-jcm-08-01179]\]. No adverse effects, as previous studies demonstrated, were seen for children in this study when 7.5 mg of crocetin was administered during the experimental period.

Although the mechanism of action of crocetin to suppress myopia progression has not been fully elucidated, there is some evidence available regarding this. Dietary crocetin was demonstrated to induce *Egr1*, which is known as a myopia-suppressive gene. In addition, a decrease of Egr1 expression resulted in AL elongation and myopic change. In the experimental murine model, AL elongation was suppressed by the oral administration of crocetin \[[@B16-jcm-08-01179]\]. In this study, AL elongation, as well as myopic refractive progression, were shown to be suppressed by the oral administration of crocetin in humans, presumably through a similar mechanism as that determined in the animal experiment.

Moreover, the choroidal thickness, which thickened upon the administration of crocetin, may possibly be related to the suppression of myopia progression. It is reported that the choroidal thickness is reduced in myopic eyes, especially in high-myopic eyes, accompanied with AL elongation \[[@B33-jcm-08-01179],[@B34-jcm-08-01179],[@B35-jcm-08-01179],[@B36-jcm-08-01179]\]. Crocetin was reported to improve blood circulation in tissues via the anti-inflammatory or antioxidant pathways, and the choroidal thickness was thought to be increased through this mechanism.

Although the rate of progression of myopia was not exactly evaluated in the samples in each group before being enrolled in the study, we selected the samples from the ordinary population without any prejudice. Meanwhile, we confirmed that the rate of myopia progression of the samples in the current study was comparable to that in other studies conducted in our country \[[@B46-jcm-08-01179]\].

The change in the choroidal thickness was not included in the linear mixed-effects model because the adjustment was performed for previously reported factors which may affect SER or AL, such as outdoor activity, near-work, age, and sex. It is unknown whether the change in choroidal thickness is the cause or the result of myopic change; therefore, it is difficult to regard choroidal thickness as a confounding factor.

There are some limitations to the current study. First, the period of this study is 24 weeks, which may be deemed relatively short; however, the result sufficiently showed statistical significance. As a pilot study, we limited the experimental term to 24 weeks. The period of 24 weeks was not long enough to evaluate the long-term effects of the supplement. It also limits the comparison with other studies. Further studies with longer terms such as one year are warranted to more effectively elucidate the effects of oral crocetin administration with possible adverse effects. Second, the time of sunlight exposure was significantly different between the two groups at the baseline, coincidentally. To adjust for this difference, a mixed-effects model was applied as the analysis technique in this study. Third, we designed the current protocol as a pilot study without sample size calculations, which was approved by IRB. Future studies for myopia control with supplements can be conducted based on the present data.

The current study demonstrates that the nutritional supplement, crocetin, may influence ocular growth by limiting axial elongation, thereby reducing refractive error progression in myopic children. The influence, however, appeared to be very small. Further studies involving a larger number of participants and longer follow-up duration are required to confirm this effect.

5. Conclusions {#sec5-jcm-08-01179}
==============

The current data showed that dietary crocetin may have a suppressive effect against myopia progression and axial elongation in children. No adverse effects associated with crocetin administration were reported during the clinical study.

6. Patent {#sec6-jcm-08-01179}
=========

Patents have been registered for the therapeutic effects of crocetin (patent no. 6502603 by Tsubota Laboratory, Inc. and Rohto Pharmaceutical Co., Ltd.).
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jcm-08-01179-t001_Table 1

###### 

Characteristics of the 138 eyes of 69 participants.

  Characteristic                           Category        All             Crocetin        Placebo        *p*--Value   
  ---------------------------------------- --------------- --------------- --------------- -------------- ------------ ----
  Number of cases                                          69              39              30                          
  Number of eyes                                           138             78              60                          
  Age (years)                                              10.2 ± 1.3      10.4 ± 1.2      10.1 ± 1.3     0.352        †
  Sex                                      boys            38 (55.1%)      22 (56.4%)      16 (53.3%)     0.812        ††
                                           girls           31 (44.9%)      17 (43.6%)      14 (46.7%)                  
  Parental myopia                          both parents    46 (66.7%)      28 (71.8%)      18 (60.0%)                  
                                           only father     11 (15.9%)      5 (12.8%)       6 (20.0%)      0.588        ††
                                           only mother     12 (17.4%)      6 (15.4%)       6 (20.0%)                   
                                           one parent      23 (33.3%)      11 (28.2%)      12 (40.0%)     0.318        ††
  Height (cm)                                              140.8 ± 9.3     141.9 ± 9.6     139.3 ± 9.0    0.250        †
  Weight (kg)                                              34.6 ± 7.7      34.9 ± 7.8      34.2 ± 7.5     0.703        †
  Best corrected visual acuity (log MAR)   −0.12 ± 0.06    −0.12 ± 0.07    −0.12 ± 0.06    0.718                       
  SER (D)                                                  −3.45 ± 0.99    −3.45 ± 0.98    −3.45 ± 1.00   0.756        
  Corneal curvature radius (mm)            7.83 ± 0.24     7.84 ± 0.25     7.83 ± 0.23     0.577                       
  Axial length (mm)                                        24.95 ± 0.83    24.91 ± 0.89    24.99 ± 0.77   0.837        
  IOP (mmHg)                                               17.2 ± 3.8      17.8 ± 3.8      16.4 ± 3.6     0.050        
  BUT (sec)                                                7.9 ± 2.1       7.8 ± 2.2       8.0 ± 2.0      0.829        
  Environmental factors                                                                                                
  Time of near-work (min/day)              205.5 ± 88.2    190.3 ± 70.9    225.2 ± 104.6   0.258                       
  Time of sunlight exposure (min/day)      53.6 ± 42.3     63.6 ± 43.2     40.5 ± 38.0     0.017                       
  Time of sleeping (hours/day)             8.8 ± 0.7       8.8 ± 0.7       8.7 ± 0.7       0.305                       
  IPAQ (METS \*min/day)                    209.1 ± 186.5   239.5 ± 203.4   169.6 ± 156.5   0.133                       

Data represent means ± SDs; min: minutes; IPAQ: International Physical Activity Questionnaire; METS: Metabolic Equivalent; log MAR: Logarithm of the Minimum Angle of Resolution; SER: spherical equivalent refraction; IOP: intraocular pressure; BUT: tear breakup time; sec: seconds; †: *t*-test; ††: Fisher test; others: Mann--Whitney U test.

jcm-08-01179-t002_Table 2

###### 

Results of the mixed-effects model fitted to 24-week SER change for both eyes (*n* = 138).

  Means                                 Estimate Value, D   Standard Error, D   95% CI   *p*-Value        
  ------------------------------------- ------------------- ------------------- -------- ---------------- ---------
  Treatments                            Crocetin            0.08                0.04     0.000\~0.155     0.049
                                        Placebo             reference           \-       \-               
  Age (years)                           6                   −0.12               0.16     −0.442\~0.196    0.446
                                        7                   −0.23               0.13     −0.497\~0.031    0.083
                                        8                   −0.21               0.08     −0.366\~-0.056   0.008
                                        9                   0.03                0.06     −0.082\~0.151    0.561
                                        10                  −0.01               0.06     −0.120\~0.097    0.838
                                        11                  0.10                0.05     −0.003\~0.202    0.056
                                        12                  reference           \-       \-               
  Sex                                   Boys                0.02                0.03     −0.047\~0.089    0.537
                                        Girls               reference           \-       \-               
  Time of near-work (min/day)           30−\<90             −0.10               0.12     −0.330\~0.141    0.428
                                        90−\<150            −0.05               0.08     −0.206\~0.116    0.581
                                        150−\<210           −0.11               0.08     −0.270\~0.051    0.178
                                        210−\<270           −0.05               0.08     −0.211\~0.115    0.563
                                        270−\<330           0.01                0.10     −0.180\~0.196    0.934
                                        330−\<390           −0.08               0.12     −0.311\~0.149    0.489
                                        390−                reference           \-       \-               
  Time of sunlight exposure (min/day)   0−\<30              −0.18               0.09     −0.364\~0.001    0.052
                                        30−\<90             −0.22               0.09     −0.400\~−0.034   0.021
                                        90−\<150            −0.24               0.10     −0.436\~−0.040   0.019
                                        150−                reference           \-       \-               
  Time of sleeping (hours/day)          7                   −0.09               0.11     −0.300\~0.118    0.391
                                        8                   −0.01               0.06     −0.125\~0.104    0.859
                                        8.5                 0.04                0.16     −0.277\~0.353    0.812
                                        9                   −0.03               0.05     −0.130\~0.079    0.627
                                        9.5                 0.13                0.09     −0.055\~0.317    0.167
                                        10                  reference           \-       \-               
  Eye                                   Left                0.04                0.03     −0.021\~0.090    0.221
                                        Right               reference           \-       \-               
  Visit weeks                           4                   0.32                0.03     0.256\~0.381     \<0.001
                                        24                  reference           \-       \-               
  SER at baseline                                           −0.01               0.02     −0.043\~0.020    0.468
  Interaction effects                                                                                     
  Visit weeks by group (= crocetin)     4                   0.01                0.04     −0.075\~0.092    0.842
                                        24                  reference           \-       \-               
  Visit weeks by group (= placebo)      4                   reference           \-       \-               
                                        24                  reference           \-       \-               

CI: confidence interval; min: minutes; SER: spherical equivalent refraction.

jcm-08-01179-t003_Table 3

###### 

The adjusted means of cycloplegic SER change and AL change in both eyes at each visit.

  -------------- ---------------------------------------------------------------------------- ---------------- -----------
  **a**          **The Adjusted Mean of Cycloplegic SER Change in both Eyes at Each Visit**                    
                 Placebo                                                                      Crocetin         
  Visit, weeks   Progression, D                                                               Progression, D   *p*-value
  4              −0.09 ± 0.05                                                                 −0.01 ± 0.05     0.028
  24             −0.41 ± 0.05                                                                 −0.33 ± 0.05     0.049
  **b**          **The Adjusted Mean of AL Change in both Eyes at Each Visit**                                 
                 Placebo                                                                      Crocetin         
  Visit, weeks   Elongation, mm                                                               Elongation, mm   *p*-value
  4              0.08 ± 0.02                                                                  0.06 ± 0.02      0.280
  12             0.16 ± 0.02                                                                  0.12 ± 0.02      0.020
  24             0.21 ± 0.02                                                                  0.18 ± 0.02      0.046
  -------------- ---------------------------------------------------------------------------- ---------------- -----------

Data are expressed as estimate values ± standard errors (SE); SER: spherical equivalent refraction; AL: axial length.

jcm-08-01179-t004_Table 4

###### 

Results of the mixed-effects model fitted to 24-week AL change for both eyes.

  Means                                 Estimate Value, mm   Standard Error, mm   95% CI   *p*-Value        
  ------------------------------------- -------------------- -------------------- -------- ---------------- ---------
  Treatments                            Crocetin             −0.03                0.01     −0.053\~−0.001   0.046
                                        Placebo              reference            \-       \-               
  Age (years)                           6                    0.20                 0.06     0.081\~0.318     0.002
                                        7                    0.10                 0.05     0.003\~0.200     0.043
                                        8                    0.12                 0.03     0.065\~0.181     \<0.001
                                        9                    0.02                 0.02     −0.028\~0.060    0.469
                                        10                   0.02                 0.02     −0.020\~0.059    0.331
                                        11                   0.00                 0.02     −0.036\~0.039    0.931
                                        12                   reference            \-       \-               
  Sex                                   Boys                 −0.03                0.01     −0.060\~−0.003   0.029
                                        Girls                reference            \-       \-               
  Time of near-work (min/day)           30--\<90             0.02                 0.04     −0.072\~0.103    0.718
                                        90--\<150            0.01                 0.03     −0.048\~0.072    0.685
                                        150--\<210           0.04                 0.03     −0.021\~0.098    0.201
                                        210--\<270           0.03                 0.03     −0.031\~0.090    0.332
                                        270--\<330           0.02                 0.04     −0.046\~0.094    0.497
                                        330--\<390           0.04                 0.04     −0.045\~0.126    0.349
                                        390−                 reference            \-       \-               
  Time of sunlight exposure (min/day)   0--\<30              0.00                 0.03     −0.067\~0.069    0.977
                                        30--\<90             −0.01                0.03     −0.076\~0.060    0.818
                                        90--\<150            −0.02                0.04     −0.091\~0.056    0.633
                                        150-                 reference            \-       \-               
  Time of sleeping (hours/day)          7                    0.01                 0.04     −0.064\~0.091    0.726
                                        8                    −0.03                0.02     −0.071\~0.013    0.165
                                        8.5                  −0.05                0.06     −0.165\~0.070    0.423
                                        9                    −0.01                0.02     −0.052\~0.026    0.491
                                        9.5                  −0.04                0.03     −0.104\~0.034    0.310
                                        10                   reference            \-       \-               
  Eye                                   Left                 0.00                 0.01     −0.011\~0.010    0.973
                                        Right                reference            \-       \-               
  Visit weeks                           4                    −0.13                0.01     −0.144\~−0.115   \<0.001
                                        12                   −0.05                0.01     −0.065\~−0.039   \<0.001
                                        24                   reference            \-       \-               
  AL at baseline                                             0.02                 0.01     0.005\~0.037     0.011
  Interaction effects                                                                                       
  Visit weeks by group (= crocetin)     4                    0.01                 0.01     −0.007\~0.032    0.205
                                        12                   −0.01                0.01     −0.022\~0.013    0.609
                                        24                   reference            \-       \-               
  Visit weeks by group (= placebo)      4                    reference            \-       \-               
                                        12                   reference            \-       \-               
                                        24                   reference            \-       \-               

CI: confidence interval; min: minutes; AL: axial length.

[^1]: These authors are contributed equally to the work and request the triple first authorship.
